{"id":417,"date":"2025-12-23T20:31:25","date_gmt":"2025-12-23T17:31:25","guid":{"rendered":"https:\/\/tabildot.com.tr\/marketrisk\/?p=417"},"modified":"2025-12-23T20:31:25","modified_gmt":"2025-12-23T17:31:25","slug":"%f0%9f%94%b4%f0%9f%87%b9%f0%9f%87%b7-oncsm-oncosem-onkolojik-sistemler-sanayi-2025-9-bilanco-analizi-finansal-ve-operasyonel-sonuclar-%f0%9f%a7%bf","status":"publish","type":"post","link":"https:\/\/tabildot.com.tr\/marketrisk\/417","title":{"rendered":"\ud83d\udd34\ud83c\uddf9\ud83c\uddf7 #ONCSM | Oncosem Onkolojik Sistemler Sanayi 2025\/9 Bilan\u00e7o Analizi | Finansal ve Operasyonel Sonu\u00e7lar \ud83e\uddff"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"\ud83d\udd34\ud83c\uddf9\ud83c\uddf7 #ONCSM | Oncosem Onkolojik Sistemler Sanayi 2025\/9 Bilan\u00e7o Analizi | Sonu\u00e7lar \ud83e\uddff\" width=\"858\" height=\"483\" src=\"https:\/\/www.youtube.com\/embed\/jw6_xJxkeF4?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<h1>Bir T\u00fcrk Sa\u011fl\u0131k Teknoloji Devinin Perde Arkas\u0131: Oncosem Hakk\u0131nda Muhtemelen Bilmedi\u011finiz 5 \u015eey<\/h1>\n<p>Kemoterapi, kanser tedavisinin en kritik ve hassas a\u015famalar\u0131ndan biridir. Hastan\u0131n ya\u015f\u0131na, kilosuna ve hastal\u0131\u011f\u0131n evresine g\u00f6re milimetrik hesaplarla haz\u0131rlanan ila\u00e7 dozlar\u0131, tedavinin ba\u015far\u0131s\u0131 i\u00e7in hayati \u00f6nem ta\u015f\u0131r. Bu s\u00fcre\u00e7te yap\u0131lacak en k\u00fc\u00e7\u00fck bir hata bile ciddi sonu\u00e7lar do\u011furabilir. Bu y\u00fczden, kemoterapi ila\u00e7lar\u0131n\u0131n haz\u0131rlanmas\u0131 mutlak bir hassasiyet ve s\u0131f\u0131r hata pay\u0131 gerektirir.<\/p>\n<p>Peki, bu y\u00fcksek riskli s\u00fcrecin perde arkas\u0131nda ne var? Hastanelerde, onkoloji servislerinde her g\u00fcn binlerce hastaya umut olan bu tedavilerin g\u00fcvenle uygulanmas\u0131n\u0131 sa\u011flayan teknolojiler ve \u015firketler genellikle g\u00f6z \u00f6n\u00fcnde olmaz. Onlar, tedavinin g\u00f6r\u00fcnmeyen kahramanlar\u0131d\u0131r.<\/p>\n<p>\u0130\u015fte bu kahramanlardan biri de, pek \u00e7o\u011fumuzun ad\u0131n\u0131 duymad\u0131\u011f\u0131 halde T\u00fcrkiye&#8217;nin sa\u011fl\u0131k sisteminde devasa bir rol oynayan, Ankara merkezli bir teknoloji \u015firketi olan <b>Oncosem<\/b>. Halka a\u00e7\u0131k bir \u015firket olmalar\u0131 sayesinde yay\u0131nlad\u0131klar\u0131 resmi raporlar, bu sessiz devin stratejik yolculu\u011funu ve ba\u015far\u0131s\u0131n\u0131n ard\u0131ndaki s\u0131rlar\u0131 g\u00f6zler \u00f6n\u00fcne seriyor. Bu raporlar\u0131 inceledi\u011fimizde kar\u015f\u0131m\u0131za \u00e7\u0131kanlar ise sadece \u015fa\u015f\u0131rt\u0131c\u0131 ger\u00e7ekler de\u011fil, ayn\u0131 zamanda ilham veren bir b\u00fcy\u00fcme hikayesi.<\/p>\n<h3><b>1. Pazar\u0131n Hakimi: T\u00fcrkiye&#8217;deki Her \u0130ki Kanser Hastas\u0131ndan Birine Dokunan G\u00fc\u00e7<\/b><\/h3>\n<p>Rakamlar bazen en \u00e7arp\u0131c\u0131 hikayeleri anlat\u0131r. Oncosem&#8217;in faaliyet raporunda yer alan bir bilgi, \u015firketin T\u00fcrkiye&#8217;deki etkisini net bir \u015fekilde ortaya koyuyor: <b>T\u00fcrkiye&#8217;de kemoterapi tedavisi g\u00f6ren her iki hastadan birinin ilac\u0131, Oncosem&#8217;in \u00fcretti\u011fi cihazlar ve setlerle haz\u0131rlan\u0131p uygulan\u0131yor.<\/b><\/p>\n<p>Bu, inan\u0131lmaz bir pazar pay\u0131 ve ayn\u0131 zamanda devasa bir sorumluluk demek. Bir d\u00fc\u015f\u00fcn\u00fcn; \u00fclkedeki kanser hastalar\u0131n\u0131n yar\u0131s\u0131n\u0131n tedavi s\u00fcrecinde, haz\u0131rlanan ilac\u0131n do\u011frulu\u011fundan uygulanan setin g\u00fcvenli\u011fine kadar her a\u015famada tek bir \u015firketin teknolojisi ve \u00fcr\u00fcnleri kritik rol oynuyor. Bu durum, Oncosem&#8217;i sadece bir t\u0131bbi cihaz \u00fcreticisi de\u011fil, ayn\u0131 zamanda ulusal onkoloji tedavisinin en temel yap\u0131 ta\u015flar\u0131ndan biri haline getiriyor.<\/p>\n<h3><b>2. Liderli\u011fin S\u0131rr\u0131: \u0130thal Etmekten \u00dcretime, &#8220;S\u0131f\u0131r Hata&#8221; Teknolojisine<\/b><\/h3>\n<p>Peki, bir \u015firket nas\u0131l olur da pazar\u0131n yar\u0131s\u0131na hakim olacak g\u00fcce ula\u015f\u0131r? Cevap, Oncosem&#8217;in stratejik d\u00f6n\u00fc\u015f\u00fcm\u00fcnde ve teknolojik \u00fcst\u00fcnl\u00fc\u011f\u00fcnde gizli. \u015eirketin amiral gemisi \u00fcr\u00fcn\u00fc olan <b>&#8220;Oncocare&#8221;<\/b> tam otomatik ila\u00e7 haz\u0131rlama cihaz\u0131, insan hatas\u0131n\u0131 en aza indirmek i\u00e7in tasarlanm\u0131\u015f ak\u0131ll\u0131 bir robot. Bu robotu benzerlerinden ay\u0131ran en kritik \u00f6zellik ise benzersiz <b>&#8220;\u00fc\u00e7l\u00fc do\u011frulama&#8221;<\/b> sistemi. Sistem, ilac\u0131 \u00fc\u00e7 farkl\u0131 a\u015famada kontrol ediyor: \u00f6nce \u015fi\u015feden \u00e7ekilirken <b>a\u011f\u0131rl\u0131\u011f\u0131n\u0131<\/b>, sonra enjekt\u00f6r i\u00e7indeyken <b>hacmini<\/b> ve son olarak hastaya verilecek torbaya aktar\u0131ld\u0131\u011f\u0131nda tekrar <b>a\u011f\u0131rl\u0131\u011f\u0131n\u0131<\/b> \u00f6l\u00e7\u00fcyor. Bu \u00fc\u00e7l\u00fc kontrol, &#8220;s\u0131f\u0131r hataya yak\u0131n&#8221; bir g\u00fcvenlik seviyesi sa\u011fl\u0131yor.<\/p>\n<p>Ancak bu teknoloji bir gecede ortaya \u00e7\u0131kmad\u0131. Oncosem&#8217;in tarih\u00e7esi, planl\u0131 bir stratejiyi g\u00f6zler \u00f6n\u00fcne seriyor. \u015eirket, 2008 y\u0131l\u0131nda bu alana <b>robotik sistemleri ithal ederek<\/b> girdi. Piyasay\u0131 ve ihtiyac\u0131 anlad\u0131ktan sonra, 2011&#8217;de kendi <b>AR-GE \u00e7al\u0131\u015fmalar\u0131n\u0131 ba\u015flatt\u0131<\/b> ve sadece iki y\u0131l sonra, 2013&#8217;te, tamamen kendi tasar\u0131m\u0131 ve \u00fcretimi olan <b>Oncocare sistemini piyasaya s\u00fcrd\u00fc.<\/b> Bu &#8220;ithal et, \u00f6\u011fren, geli\u015ftir ve \u00fcret&#8221; stratejisi, Oncosem&#8217;i bir distrib\u00fct\u00f6r olmaktan \u00e7\u0131kar\u0131p, pazar\u0131n kurallar\u0131n\u0131 belirleyen bir teknoloji liderine d\u00f6n\u00fc\u015ft\u00fcrd\u00fc.<\/p>\n<h3><b>3. Krizde \u00c7eviklik: Onkolojiden COVID Test Kitlerine Uzanan \u00dcretim Kabiliyeti<\/b><\/h3>\n<p>Bir \u015firketin ne kadar \u00e7evik ve uyumlu oldu\u011funu, kriz zamanlar\u0131nda att\u0131\u011f\u0131 ad\u0131mlar belirler. Oncosem&#8217;in \u015firket tarih\u00e7esini inceledi\u011fimizde, 2020 y\u0131l\u0131na ait bir sat\u0131r dikkat \u00e7ekiyor: <b>&#8220;CRT ve CAT markalar\u0131yla Covid-19 H\u0131zl\u0131 Test Kiti \u00dcretimi.&#8221;<\/b><\/p>\n<p>T\u00fcm d\u00fcnyan\u0131n COVID-19 pandemisiyle m\u00fccadele etti\u011fi bir d\u00f6nemde, ana uzmanl\u0131k alan\u0131 onkoloji sistemleri olan bir \u015firketin h\u0131zl\u0131 bir manevrayla test kiti \u00fcretimine ge\u00e7mesi, ezber bozan bir hamle. Bu durum, \u015firketin sadece belirli bir alanda de\u011fil, genel olarak medikal \u00fcretim konusunda ne kadar esnek ve geli\u015fmi\u015f bir altyap\u0131ya sahip oldu\u011funu g\u00f6steriyor. Onkoloji gibi son derece spesifik bir alanda edindikleri \u00fcretim disiplinini ve teknolojik yetkinli\u011fi, k\u00fcresel bir sa\u011fl\u0131k krizine an\u0131nda yan\u0131t verebilmek i\u00e7in kullanmalar\u0131, \u015firketin adaptasyon kabiliyetinin en net kan\u0131t\u0131.<\/p>\n<h3><b>4. \u0130novasyonun Meyvesi: Ankara&#8217;da Geli\u015ftirilen &#8220;IVein&#8221; ile Londra&#8217;n\u0131n Zirvesine<\/b><\/h3>\n<p>Oncosem&#8217;in inovasyon g\u00fcc\u00fc, onkolojiyle s\u0131n\u0131rl\u0131 de\u011fil. \u015eirket, <b>&#8220;IVein&#8221;<\/b> markas\u0131 alt\u0131nda \u00fcretti\u011fi <b>i\u011fnesiz damar yolu (IV) uzatma setleri<\/b> ile medikal teknoloji alan\u0131nda yeni bir ba\u015far\u0131 hikayesi yazd\u0131. Bu \u00fcr\u00fcnler, damar yoluyla yap\u0131lan tedavilerde enfeksiyon riskini en aza indirerek hem hasta hem de sa\u011fl\u0131k \u00e7al\u0131\u015fan\u0131 i\u00e7in g\u00fcvenli\u011fi art\u0131r\u0131yor. %95 gibi y\u00fcksek bir yerlilik oran\u0131yla \u00fcretilen IVein, T\u00fcrkiye pazar\u0131na girer girmez b\u00fcy\u00fck bir ba\u015far\u0131 yakalad\u0131 ve y\u00fczlerce kamu ihalesinde %70&#8217;in \u00fczerinde bir kazanma oran\u0131 elde etti.<\/p>\n<p>Ancak bu yerel ba\u015far\u0131, \u00e7ok daha b\u00fcy\u00fck bir hedefin yaln\u0131zca ilk ad\u0131m\u0131yd\u0131. Yerli pazarda kan\u0131tlanan bu ba\u015far\u0131, uluslararas\u0131 bir kap\u0131y\u0131 aralad\u0131. Ekim 2025&#8217;te \u015firket, \u0130ngiltere&#8217;nin d\u00fcnyaca \u00fcnl\u00fc Ulusal Sa\u011fl\u0131k Sistemi&#8217;nin (NHS) a\u00e7t\u0131\u011f\u0131 dev bir ihaleyi kazand\u0131\u011f\u0131n\u0131 duyurdu. \u0130halenin ad\u0131: <b>&#8220;\u0130\u011fnesiz Ba\u011flant\u0131 Sistemleri ve \u0130li\u015fkili \u00dcr\u00fcnler 2025&#8221;<\/b>. Oncosem, teklif verdi\u011fi <b>97 kalemin tamam\u0131nda<\/b> ba\u015far\u0131l\u0131 tedarik\u00e7i olarak se\u00e7ildi. Toplam b\u00fct\u00e7esi <b>115 Milyon Sterlin<\/b> olan ve <b>704 hastaneyi<\/b> kapsayan bu s\u00f6zle\u015fme, Ankara&#8217;da geli\u015ftirilen bir inovasyonun, d\u00fcnyan\u0131n en zorlu sa\u011fl\u0131k pazarlar\u0131ndan birini nas\u0131l fethedebilece\u011finin somut bir \u00f6rne\u011fi oldu.<\/p>\n<h3><b>5. Rekabet Avantaj\u0131: Her \u015eeyi Kendi Yapan \u015eirket<\/b><\/h3>\n<p>T\u00fcm bu ba\u015far\u0131lar\u0131n arkas\u0131nda yatan gizli bir g\u00fc\u00e7 daha var: <b>teknolojik kendi kendine yeterlilik.<\/b> Faaliyet raporunun sat\u0131r aralar\u0131nda gizlenmi\u015f, ancak \u015firketin stratejisini anlamak i\u00e7in kritik olan bir c\u00fcmle yer al\u0131yor: <b>&#8220;Kullan\u0131lan t\u00fcm sistemlerin yaz\u0131l\u0131mlar\u0131 \u015firketin bilgi teknolojileri ekibi taraf\u0131ndan yap\u0131lmaktad\u0131r.&#8221;<\/b><\/p>\n<p>Bu, Oncosem&#8217;in sadece bir donan\u0131m \u00fcreticisi olmad\u0131\u011f\u0131n\u0131, ayn\u0131 zamanda bir yaz\u0131l\u0131m \u015firketi oldu\u011funu g\u00f6steriyor. Robotik cihazlar\u0131, hassas \u00f6l\u00e7\u00fcm sistemleri ve bu sistemleri y\u00f6neten t\u00fcm yaz\u0131l\u0131mlar\u0131 kendi b\u00fcnyesinde geli\u015ftirmesi, \u015firkete inan\u0131lmaz bir esneklik ve rekabet avantaj\u0131 sa\u011fl\u0131yor. Donan\u0131m ve yaz\u0131l\u0131m aras\u0131ndaki bu kusursuz entegrasyon, hem &#8220;\u00fc\u00e7l\u00fc do\u011frulama&#8221; gibi hassas sistemlerin geli\u015ftirilmesini hem de pazar\u0131n ihtiya\u00e7lar\u0131na h\u0131zla cevap verebilmelerini sa\u011fl\u0131yor. Bu derin dikey entegrasyon, Oncosem&#8217;in hassasiyetini, \u00e7evikli\u011fini ve inovasyon g\u00fcc\u00fcn\u00fc besleyen ana motor g\u00f6revini g\u00f6r\u00fcyor.<\/p>\n<h3><b>Sonu\u00e7: Rakamlar\u0131n Ard\u0131ndaki Vizyon<\/b><\/h3>\n<p>Bir \u015firketin faaliyet raporlar\u0131, genellikle sadece rakamlarla dolu belgeler olarak g\u00f6r\u00fcl\u00fcr. Ancak Oncosem \u00f6rne\u011finde, bu rakamlar ithalatla ba\u015flayan, AR-GE ile devam eden, yerli \u00fcretimle pazar liderli\u011fine ula\u015fan ve nihayetinde k\u00fcresel bir oyuncu haline gelen bir \u015firketin stratejik yol haritas\u0131n\u0131 \u00e7iziyor.<\/p>\n<p>Ankara&#8217;da ba\u015flayan bu yolculu\u011fun, bug\u00fcn T\u00fcrkiye&#8217;deki her iki kanser hastas\u0131ndan birine dokunup Londra&#8217;daki y\u00fczlerce hastaneye uzanmas\u0131, dikkat \u00e7ekici bir ba\u015far\u0131 \u00f6yk\u00fcs\u00fc. Bu da akla \u015fu soruyu getiriyor: Bir sonraki b\u00fcy\u00fck sa\u011fl\u0131k teknolojisi at\u0131l\u0131m\u0131, hi\u00e7 beklemedi\u011fimiz bir yerden, belki de yan\u0131 ba\u015f\u0131m\u0131zdaki bir sanayi b\u00f6lgesinden \u00e7\u0131kabilir mi?<\/p>\n<p>&nbsp;<\/p>\n<h1><span style=\"color: #0000ff;\">Oncosem Onkolojik Sistemler A.\u015e. Faaliyet ve Finansal Durum De\u011ferlendirmesi<\/span><\/h1>\n<h2>Y\u00f6netici \u00d6zeti<\/h2>\n<p>Bu brifing, Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.\u015e.&#8217;nin 01.01.2025 \u2013 30.09.2025 d\u00f6nemine ait faaliyet raporu ve finansal tablolar\u0131n\u0131 sentezleyerek \u015firketin stratejik konumunu, operasyonel ba\u015far\u0131lar\u0131n\u0131 ve finansal performans\u0131n\u0131 analiz etmektedir. \u015eirket, onkoloji alan\u0131nda tam otomatik kemoterapi ila\u00e7 haz\u0131rlama sistemleri, ilgili sarf malzemeler ve hizmet sunumu konular\u0131nda T\u00fcrkiye pazar\u0131n\u0131n lideri konumundad\u0131r. T\u00fcrkiye&#8217;deki kemoterapi pazar\u0131n\u0131n yakla\u015f\u0131k yar\u0131s\u0131n\u0131 elinde bulunduran Oncosem, her iki kanser hastas\u0131ndan birinin tedavisinde kullan\u0131lan ila\u00e7lar\u0131n haz\u0131rlanmas\u0131nda rol oynamaktad\u0131r.<\/p>\n<p>D\u00f6nemin en kritik geli\u015fmesi, \u015firketin &#8220;IVein&#8221; markas\u0131 alt\u0131nda %95 yerlilik oran\u0131yla \u00fcretti\u011fi i\u011fnesiz valfli IV uzatma setleri ile hem i\u00e7 pazarda hem de uluslararas\u0131 alanda elde etti\u011fi b\u00fcy\u00fck ba\u015far\u0131d\u0131r. Bu \u00fcr\u00fcn grubu, Devlet Malzeme Ofisi (DMO) ile yap\u0131lan \u00e7er\u00e7eve anla\u015fmas\u0131 ve kazan\u0131lan \u00e7ok say\u0131da kamu ihalesiyle yurt i\u00e7inde g\u00fc\u00e7l\u00fc bir pazar pay\u0131 elde etmi\u015ftir. Uluslararas\u0131 alanda ise \u0130ngiltere Ulusal Sa\u011fl\u0131k Hizmetleri (NHS) ile imzalanan 115 milyon GBP b\u00fct\u00e7eli ve 2+2 y\u0131l s\u00fcreli \u00e7er\u00e7eve s\u00f6zle\u015fmesi, \u015firketin k\u00fcresel pazardaki b\u00fcy\u00fcme stratejisinin en somut g\u00f6stergesidir.<\/p>\n<p>Finansal olarak \u015firket, bir \u00f6nceki y\u0131l\u0131n ayn\u0131 d\u00f6nemindeki 66,1 milyon TL&#8217;lik zarara kar\u015f\u0131l\u0131k, 2025&#8217;in ilk dokuz ay\u0131nda 25,5 milyon TL net k\u00e2r elde ederek g\u00fc\u00e7l\u00fc bir geri d\u00f6n\u00fc\u015f sergilemi\u015ftir. Has\u0131lat, %41&#8217;lik bir art\u0131\u015fla 370,5 milyon TL&#8217;den 523,4 milyon TL&#8217;ye y\u00fckselmi\u015ftir. Bu performans, yeni \u00fcr\u00fcnlerin pazara ba\u015far\u0131l\u0131 bir \u015fekilde sunulmas\u0131 ve kazan\u0131lan y\u00fcksek hacimli ihalelerle desteklenmi\u015ftir.<\/p>\n<p>\u015eirket, Almanya, \u0130ngiltere ve \u00d6zbekistan&#8217;da kurdu\u011fu ba\u011fl\u0131 ortakl\u0131klar ve Ukrayna&#8217;daki i\u015ftiraki ile uluslararas\u0131 varl\u0131\u011f\u0131n\u0131 peki\u015ftirmektedir. \u00d6zellikle Oncosem UK Limited&#8217;in sermayesinin d\u00f6nem i\u00e7inde ve sonras\u0131nda birden fazla kez art\u0131r\u0131lmas\u0131, \u0130ngiltere pazar\u0131ndaki b\u00fcy\u00fcme potansiyeline y\u00f6nelik stratejik yat\u0131r\u0131mlar\u0131 i\u015faret etmektedir. Dikey entegre \u00fcretim modeli, g\u00fc\u00e7l\u00fc Ar-Ge kabiliyeti ve maliyet avantaj\u0131 sa\u011flayan yerli \u00fcretim altyap\u0131s\u0131, Oncosem&#8217;in sekt\u00f6rdeki rekabet avantaj\u0131n\u0131 s\u00fcrd\u00fcrmesini sa\u011flayan temel unsurlard\u0131r.<\/p>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>1. \u015eirket Profili ve Faaliyet Alanlar\u0131<\/h2>\n<h3>1.1. Genel Bak\u0131\u015f ve Tarih\u00e7e<\/h3>\n<p>05.03.2008 tarihinde kurulan Oncosem Onkolojik Sistemler San. ve Tic. A.\u015e., medikal teknoloji alan\u0131nda, \u00f6zellikle onkoloji tedavilerinde kullan\u0131lan sistemlerin \u00fcretimi ve hizmet sunumu \u00fczerine odaklanm\u0131\u015f bir \u015firkettir. Ankara merkezli olan \u015firket, \u00fcretim faaliyetlerini Anadolu OSB&#8217;deki 10.000 m\u00b2&#8217;lik fabrikas\u0131nda s\u00fcrd\u00fcrmektedir.<\/p>\n<p><b>\u00d6nemli Tarihsel Geli\u015fmeler:<\/b><\/p>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>Y\u0131l<\/td>\n<td>Geli\u015fme<\/td>\n<\/tr>\n<tr>\n<td><b>2008<\/b><\/td>\n<td>Oncosem A.\u015e. kuruldu ve medikal tekstil \u00fcretimine ba\u015flad\u0131. T\u00fcrkiye&#8217;ye ilk robotik kemoterapi ila\u00e7 haz\u0131rlama sistemlerini ithal etti.<\/td>\n<\/tr>\n<tr>\n<td><b>2011<\/b><\/td>\n<td>Kemoterapi ila\u00e7 haz\u0131rlama sistemleri i\u00e7in Ar-Ge \u00e7al\u0131\u015fmalar\u0131na ba\u015fland\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2013<\/b><\/td>\n<td>&#8220;Oncocare&#8221; markas\u0131yla tam otomatik ila\u00e7 haz\u0131rlama sistemlerinin \u00fcretimine ba\u015fland\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2015<\/b><\/td>\n<td>\u00dcr\u00fcnler SGK Sa\u011fl\u0131k Uygulama Tebli\u011fi (SUT) kapsam\u0131na al\u0131narak piyasaya girdi.<\/td>\n<\/tr>\n<tr>\n<td><b>2017<\/b><\/td>\n<td>Kemoterapi ila\u00e7 haz\u0131rlama set ve sarf malzemelerinin \u00fcretimine ba\u015fland\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2018<\/b><\/td>\n<td>\u015eirket, T\u00fcrkiye pazar\u0131nda lider konuma ula\u015ft\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2021<\/b><\/td>\n<td>Almanya&#8217;da Oncosem GmbH kuruldu ve pazar pay\u0131 %50&#8217;ye ula\u015ft\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2023<\/b><\/td>\n<td>&#8220;Oncocare Plus&#8221; kemoterapi ila\u00e7 haz\u0131rlama sistemi \u00fcretimine ba\u015fland\u0131.<\/td>\n<\/tr>\n<tr>\n<td><b>2024<\/b><\/td>\n<td>&#8220;IVein&#8221; markas\u0131 alt\u0131nda i\u011fnesiz enjeksiyon valfli IV uzatma setleri \u00fcretimine ba\u015fland\u0131.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>1.2. Faaliyet Konular\u0131 ve Hizmet Modeli<\/h3>\n<p>\u015eirketin ana faaliyetleri, esas s\u00f6zle\u015fmesinde belirtildi\u011fi \u00fczere, medikal ve t\u0131bbi cihazlar\u0131n, yedek par\u00e7alar\u0131n ve sarf malzemelerinin \u00fcretimi, sat\u0131\u015f\u0131, kiralanmas\u0131 ve ithalat\/ihracat\u0131n\u0131 kapsamaktad\u0131r. Fiili olarak y\u00fcr\u00fct\u00fclen i\u015f kollar\u0131 \u015funlard\u0131r:<\/p>\n<ul>\n<li><b>Tam Otomatik Kemoterapi \u0130la\u00e7 Haz\u0131rlama Cihazlar\u0131:<\/b> &#8220;Oncocare&#8221; markas\u0131 alt\u0131nda cihazlar\u0131n \u00fcretimi.<\/li>\n<li><b>Sarf Malzemeleri:<\/b> Kemoterapi ila\u00e7 haz\u0131rlama ve uygulama setleri ile ba\u011flant\u0131 aparatlar\u0131n\u0131n \u00fcretimi.<\/li>\n<li><b>Hizmet Sunumu:<\/b> Kamu, \u00fcniversite ve \u00f6zel hastanelerde kemoterapi ila\u00e7 haz\u0131rlama \u00fcnitelerinin (temiz oda kurulumu dahil) kurulmas\u0131 ve i\u015fletilmesi. Bu hizmetler, genellikle %100 ba\u011fl\u0131 ortakl\u0131\u011f\u0131 olan Santek Sa\u011fl\u0131k Turizm Tekstil San. ve Tic. A.\u015e. \u00fczerinden, ihaleler yoluyla y\u00fcr\u00fct\u00fclmektedir.<\/li>\n<li><b>Di\u011fer \u00dcr\u00fcnler:<\/b> Cerrahi maske ve h\u0131zl\u0131 antijen\/antikor test kitleri \u00fcretimi.<\/li>\n<\/ul>\n<p>Hizmet modeli, hastanelere tahsis edilen bir alanda temiz oda kurulumu ile ba\u015flar. Ard\u0131ndan Oncocare cihazlar\u0131 kurulur ve Oncosem taraf\u0131ndan \u00fcretilen setler ile donat\u0131l\u0131r. \u0130la\u00e7 haz\u0131rlama i\u015flemi, Oncosem veya Santek personeli taraf\u0131ndan, hekimin belirledi\u011fi protokole g\u00f6re yap\u0131l\u0131r ve haz\u0131rlanan ila\u00e7, hastane personeli taraf\u0131ndan hastaya uygulan\u0131r. Faturaland\u0131rma, ay sonunda hasta ba\u015f\u0131na haz\u0131rlanan ila\u00e7 bedeli \u00fczerinden hak edi\u015f d\u00fczenlenerek yap\u0131l\u0131r.<\/p>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>2. \u00dcr\u00fcn ve Hizmet Portf\u00f6y\u00fc<\/h2>\n<p>Oncosem, kemoterapi tedavi s\u00fcrecinin tamam\u0131n\u0131 kapsayan entegre bir \u00fcr\u00fcn ve hizmet portf\u00f6y\u00fc sunmaktad\u0131r.<\/p>\n<h3>2.1. Oncocare Otomatik Kemoterapi \u0130la\u00e7 Haz\u0131rlama Cihaz\u0131<\/h3>\n<ul>\n<li><b>Tan\u0131m:<\/b> Operat\u00f6r m\u00fcdahalesi olmadan, hassas \u00f6l\u00e7\u00fcmlerle kemoterapi ila\u00e7lar\u0131n\u0131 haz\u0131rlayan tam otomatik bir cihazd\u0131r.<\/li>\n<li><b>\u00d6zellikler:<\/b>\n<ul>\n<li><b>Mod\u00fcler Yap\u0131:<\/b> Hastane kapasitesine g\u00f6re 2 veya 4 mod\u00fcll\u00fc se\u00e7enekler sunar.<\/li>\n<li><b>\u00dc\u00e7l\u00fc Do\u011frulama Sistemi (STVS):<\/b> \u0130la\u00e7 miktar\u0131n\u0131 a\u011f\u0131rl\u0131k (\u015fi\u015feden eksilen ve torbaya giden) ve hacim (enjekt\u00f6re \u00e7ekilen) olarak \u00fc\u00e7 farkl\u0131 noktada \u00f6l\u00e7erek hata pay\u0131n\u0131 en aza indirir.<\/li>\n<li><b>G\u00fcvenlik:<\/b> Kontaminasyonu \u00f6nleyen havaland\u0131rma \u00fcnitesi ve el de\u011fmeden at\u0131k y\u00f6netimi sa\u011flayan entegre at\u0131k sistemi bulunur.<\/li>\n<\/ul>\n<\/li>\n<li><b>Tan\u0131n\u0131rl\u0131k:<\/b> 2014 y\u0131l\u0131nda T.C. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 taraf\u0131ndan &#8220;Kanser \u00d6d\u00fcl\u00fc&#8221;ne lay\u0131k g\u00f6r\u00fclm\u00fc\u015f ve 2015&#8217;te SUT geri \u00f6deme kapsam\u0131na al\u0131nm\u0131\u015ft\u0131r.<\/li>\n<\/ul>\n<h3>2.2. Kemoterapi \u0130la\u00e7 Haz\u0131rlama ve Uygulama Setleri<\/h3>\n<p>\u015eirket, cihazlarla tam uyumlu olarak \u00e7al\u0131\u015fan 50&#8217;den fazla \u00e7e\u015fit kapal\u0131 sistem set ve ba\u011flant\u0131 aparat\u0131 \u00fcretmektedir.<\/p>\n<ul>\n<li><b>Ana Bile\u015fenler:<\/b> EVA Torbalar, flakon adapt\u00f6rleri (Oncovial), i\u011fnesiz enjeksiyon valfleri (Oncovalve) ve ba\u011flant\u0131 hatlar\u0131ndan (Spike) olu\u015fur.<\/li>\n<li><b>Malzeme:<\/b> T\u00fcm \u00fcr\u00fcnler, kemoterapi ila\u00e7lar\u0131 ile etkile\u015fime girmeyen, \u0131\u015f\u0131ktan korumal\u0131 medikal hammaddelerden \u00fcretilmektedir.<\/li>\n<li><b>Kalite Standartlar\u0131:<\/b> \u00dcretim s\u00fcreci ISO 13485 T\u0131bbi Malzeme Kalite Y\u00f6netim Sistemine uygun olarak y\u00fcr\u00fct\u00fclmekte ve \u00fcr\u00fcnler 93\/42\/EEC T\u0131bbi Cihaz Y\u00f6netmeli\u011fi do\u011frultusunda CE sertifikas\u0131na sahiptir.<\/li>\n<\/ul>\n<h3>2.3. IVein \u0130\u011fnesiz Valfli IV Uzatma Setleri<\/h3>\n<ul>\n<li><b>Tan\u0131m:<\/b> 2025 y\u0131l\u0131 ba\u015f\u0131nda piyasaya s\u00fcr\u00fclen, IV s\u0131v\u0131, ila\u00e7 ve kan inf\u00fczyonunda g\u00fcvenli eri\u015fim sa\u011flayan kapal\u0131, i\u011fnesiz uzatma setleridir.<\/li>\n<li><b>Stratejik \u00d6nem:<\/b> %95 yerlilik oran\u0131 ile \u00fcretilen bu \u00fcr\u00fcn grubu, \u015firketin onkoloji d\u0131\u015f\u0131ndaki hastane departmanlar\u0131na (yo\u011fun bak\u0131m, anestezi, pediatri vb.) a\u00e7\u0131lmas\u0131n\u0131 sa\u011flam\u0131\u015ft\u0131r.<\/li>\n<li><b>Pazar Ba\u015far\u0131s\u0131:<\/b> Piyasaya giri\u015finin ilk aylar\u0131nda 350&#8217;den fazla kamu ihalesinde %70 ba\u015far\u0131 oran\u0131 yakalam\u0131\u015f, DMO ile \u00e7er\u00e7eve anla\u015fmas\u0131 imzalam\u0131\u015f ve en \u00f6nemlisi \u0130ngiltere NHS ihalesini kazanm\u0131\u015ft\u0131r.<\/li>\n<\/ul>\n<h3>2.4. Di\u011fer \u00dcr\u00fcnler ve Hizmetler<\/h3>\n<ul>\n<li><b>Oncowaste:<\/b> Tehlikeli ve sitotoksik at\u0131klar\u0131n el de\u011fmeden m\u00fch\u00fcrlenerek paketlenmesini sa\u011flayan bir at\u0131k toplama cihaz\u0131d\u0131r.<\/li>\n<li><b>\u0130nf\u00fczyon Pompas\u0131:<\/b> &#8220;Oncocare&#8221; markas\u0131yla yurt d\u0131\u015f\u0131nda \u00fcrettirilen ve hizmet verilen hastanelere bedelsiz kurulan, yaz\u0131l\u0131m\u0131 \u015firket i\u00e7inde geli\u015ftirilen pompalard\u0131r.<\/li>\n<li><b>Diagnostik \u00dcr\u00fcnler ve Maske:<\/b> Salg\u0131n hastal\u0131klar i\u00e7in CRT ve CAT markal\u0131 h\u0131zl\u0131 test kitleri ve cerrahi maske \u00fcretimi yapmaktad\u0131r.<\/li>\n<\/ul>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>3. Kurumsal Yap\u0131 ve Y\u00f6netim<\/h2>\n<h3>3.1. Sermaye ve Ortakl\u0131k Yap\u0131s\u0131<\/h3>\n<ul>\n<li><b>\u00c7\u0131kar\u0131lm\u0131\u015f Sermaye:<\/b> 23.850.000 TL<\/li>\n<li><b>Kay\u0131tl\u0131 Sermaye Tavan\u0131:<\/b> 99.000.000 TL (2022-2026 i\u00e7in ge\u00e7erli)<\/li>\n<li><b>Pay Yap\u0131s\u0131:<\/b> A grubu nama yaz\u0131l\u0131 (3.980.000 adet) ve B grubu hamiline yaz\u0131l\u0131 (19.870.000 adet) hisselerden olu\u015fmaktad\u0131r. A grubu paylar\u0131n y\u00f6netim kuruluna aday g\u00f6sterme ve genel kurulda 5 kat oy imtiyaz\u0131 bulunmaktad\u0131r.<\/li>\n<\/ul>\n<p><b>30.09.2025 \u0130tibar\u0131yla Ortakl\u0131k ve Oy Hakk\u0131 Yap\u0131s\u0131:<\/b><\/p>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>Hissedar<\/td>\n<td>Pay Grubu<\/td>\n<td>Pay Tutar\u0131 (TL)<\/td>\n<td>Pay Oran\u0131 (%)<\/td>\n<td>Oy Hakk\u0131<\/td>\n<td>Oy Oran\u0131 (%)<\/td>\n<\/tr>\n<tr>\n<td>Erol \u00c7EL\u0130K<\/td>\n<td>A<\/td>\n<td>3.980.000<\/td>\n<td>16,69<\/td>\n<td>19.900.000<\/td>\n<td>50,04<\/td>\n<\/tr>\n<tr>\n<td>Erol \u00c7EL\u0130K<\/td>\n<td>B<\/td>\n<td>11.215.000<\/td>\n<td>47,02<\/td>\n<td>11.215.000<\/td>\n<td>28,20<\/td>\n<\/tr>\n<tr>\n<td>Di\u011fer<\/td>\n<td>B<\/td>\n<td>8.655.000<\/td>\n<td>36,29<\/td>\n<td>8.655.000<\/td>\n<td>21,76<\/td>\n<\/tr>\n<tr>\n<td><b>Toplam<\/b><\/td>\n<td><b>A+B<\/b><\/td>\n<td><b>23.850.000<\/b><\/td>\n<td><b>100,00<\/b><\/td>\n<td><b>39.770.000<\/b><\/td>\n<td><b>100,00<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>3.2. Ba\u011fl\u0131 Ortakl\u0131klar ve \u0130\u015ftirakler<\/h3>\n<p>Oncosem, hem yurt i\u00e7i operasyonlar\u0131n\u0131 desteklemek hem de uluslararas\u0131 pazarlara a\u00e7\u0131lmak amac\u0131yla stratejik ortakl\u0131klar kurmu\u015ftur.<\/p>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>\u015eirket Ad\u0131<\/td>\n<td>Faaliyet Yeri<\/td>\n<td>Faaliyet Konusu<\/td>\n<td>Oncosem Pay\u0131 (%)<\/td>\n<\/tr>\n<tr>\n<td>Santek Sa\u011fl\u0131k Turz. Teks. San. ve Tic A.\u015e.<\/td>\n<td>T\u00fcrkiye<\/td>\n<td>T\u0131bbi cihaz pazarlama ve sat\u0131\u015f\u0131<\/td>\n<td>100<\/td>\n<\/tr>\n<tr>\n<td>Oncosem GmBH<\/td>\n<td>Almanya<\/td>\n<td>Kemoterapi ila\u00e7 haz\u0131rlama hizmeti<\/td>\n<td>100<\/td>\n<\/tr>\n<tr>\n<td>Oncosem UK Limited<\/td>\n<td>\u0130ngiltere<\/td>\n<td>Kemoterapi ila\u00e7 haz\u0131rlama hizmeti ve malzeme sat\u0131\u015f\u0131<\/td>\n<td>100<\/td>\n<\/tr>\n<tr>\n<td>Oncosem CA LLC<\/td>\n<td>\u00d6zbekistan<\/td>\n<td>Kemoterapi ve ileri tan\u0131 tedavi hizmeti<\/td>\n<td>100<\/td>\n<\/tr>\n<tr>\n<td>Oncosem Ukraine<\/td>\n<td>Ukrayna<\/td>\n<td>Kemoterapi ila\u00e7 haz\u0131rlama hizmeti<\/td>\n<td>20<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>3.3. Y\u00f6netim Kurulu ve Komiteler<\/h3>\n<p>\u015eirket, TTK ve SPK mevzuat\u0131na uygun olarak olu\u015fturulmu\u015f bir y\u00f6netim yap\u0131s\u0131na sahiptir. Y\u00f6netim Kurulu, Erol \u00c7EL\u0130K ba\u015fkanl\u0131\u011f\u0131nda 9 \u00fcyeden olu\u015fmaktad\u0131r ve 3 \u00fcyesi ba\u011f\u0131ms\u0131z \u00fcyedir. Y\u00f6netim Kurulu b\u00fcnyesinde Denetim Komitesi, Riskin Erken Saptanmas\u0131 Komitesi ve Kurumsal Y\u00f6netim Komitesi (Aday G\u00f6sterme ve \u00dccret Komitesi g\u00f6revlerini de \u00fcstlenir) faaliyet g\u00f6stermektedir.<\/p>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>4. Pazar Analizi ve Stratejik Konumland\u0131rma<\/h2>\n<h3>4.1. Sekt\u00f6r De\u011ferlendirmesi<\/h3>\n<ul>\n<li><b>T\u00fcrkiye Sa\u011fl\u0131k Harcamalar\u0131:<\/b> T\u00dc\u0130K verilerine g\u00f6re, T\u00fcrkiye&#8217;de toplam sa\u011fl\u0131k harcamalar\u0131 2023 y\u0131l\u0131nda %105 artarak 1,24 trilyon TL&#8217;ye ula\u015fm\u0131\u015ft\u0131r. Ki\u015fi ba\u015f\u0131 sa\u011fl\u0131k harcamas\u0131 ise %104,2 art\u0131\u015fla 14.582 TL olmu\u015ftur. Bu art\u0131\u015f, sekt\u00f6rdeki b\u00fcy\u00fcme potansiyelini g\u00f6stermektedir.<\/li>\n<li><b>Global Kanser Vakalar\u0131:<\/b> Uluslararas\u0131 Kanser Ara\u015ft\u0131rma Ajans\u0131 (IARC) raporuna g\u00f6re, 2022&#8217;de d\u00fcnya genelinde 20 milyon yeni vaka g\u00f6r\u00fclm\u00fc\u015f ve bu say\u0131n\u0131n 2050&#8217;de 35 milyonu a\u015faca\u011f\u0131 \u00f6ng\u00f6r\u00fclmektedir. Bu durum, onkoloji tedavilerine y\u00f6nelik pazar\u0131n b\u00fcy\u00fcmesini ka\u00e7\u0131n\u0131lmaz k\u0131lmaktad\u0131r.<\/li>\n<li><b>Kemoterapi Pazar\u0131:<\/b> Kemoterapi ila\u00e7lar\u0131n\u0131n toksik yap\u0131s\u0131, hassas dozaj gerektirmesi ve haz\u0131rlanma s\u00fcrecindeki riskler, Oncosem&#8217;in sundu\u011fu otomatik, kapal\u0131 ve g\u00fcvenli sistemlere olan talebi art\u0131rmaktad\u0131r. T\u00fcrkiye&#8217;de ilgili hizmetler SUT kapsam\u0131nda geri \u00f6denmektedir. \u015eirket, T\u00fcrkiye pazar\u0131n\u0131n yakla\u015f\u0131k %48&#8217;ini kontrol etmektedir.<\/li>\n<\/ul>\n<h3>4.2. Rekabet Avantajlar\u0131<\/h3>\n<ul>\n<li><b>Dikey Entegrasyon:<\/b> Cihaz, yaz\u0131l\u0131m, set ve sarf malzemelerin tamam\u0131n\u0131n \u015firket b\u00fcnyesinde tasarlan\u0131p \u00fcretilmesi, maliyet avantaj\u0131 ve sistem uyumlulu\u011fu sa\u011flamaktad\u0131r.<\/li>\n<li><b>Maliyet Liderli\u011fi:<\/b> T\u00fcrkiye&#8217;deki i\u015f\u00e7ilik maliyetlerinin d\u00fc\u015f\u00fckl\u00fc\u011f\u00fc ve yerli \u00fcretim, \u015firkete hem i\u00e7 pazarda hem de ihracatta rekabet\u00e7i fiyatland\u0131rma imkan\u0131 tan\u0131maktad\u0131r.<\/li>\n<li><b>Ni\u015f Pazar:<\/b> Otomatik kemoterapi ila\u00e7 haz\u0131rlama sistemleri pazar\u0131nda d\u00fcnya genelinde az say\u0131da \u00fcretici bulunmas\u0131, \u015firketin rekabet bask\u0131s\u0131n\u0131 azaltmaktad\u0131r.<\/li>\n<li><b>Fikri M\u00fclkiyet:<\/b> \u00dcr\u00fcnlere ait tasar\u0131m tescil belgeleri ve patentler, \u015firkete yasal koruma ve rekabet avantaj\u0131 sa\u011flamaktad\u0131r.<\/li>\n<li><b>Esneklik ve Uzmanl\u0131k:<\/b> Kendi b\u00fcnyesindeki m\u00fchendislik ve klinik ekipleri sayesinde m\u00fc\u015fteri taleplerine h\u0131zla yan\u0131t verebilmekte ve olas\u0131 sorunlara etkin \u00e7\u00f6z\u00fcmler \u00fcretebilmektedir.<\/li>\n<\/ul>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>5. Finansal Performans Analizi<\/h2>\n<p>\u015eirket, 2025 y\u0131l\u0131n\u0131n ilk dokuz ay\u0131nda g\u00fc\u00e7l\u00fc bir finansal performans sergilemi\u015ftir.<\/p>\n<h3>5.1. Finansal Durum Tablosu (Konsolide)<\/h3>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>(TL)<\/td>\n<td>30 Eyl\u00fcl 2025<\/td>\n<td>31 Aral\u0131k 2024<\/td>\n<\/tr>\n<tr>\n<td>D\u00f6nen Varl\u0131klar<\/td>\n<td>335.086.503<\/td>\n<td>273.579.360<\/td>\n<\/tr>\n<tr>\n<td>Duran Varl\u0131klar<\/td>\n<td>210.410.830<\/td>\n<td>206.744.969<\/td>\n<\/tr>\n<tr>\n<td><b>Toplam Varl\u0131klar<\/b><\/td>\n<td><b>545.497.333<\/b><\/td>\n<td><b>480.324.329<\/b><\/td>\n<\/tr>\n<tr>\n<td>K\u0131sa Vadeli Y\u00fck\u00fcml\u00fcl\u00fckler<\/td>\n<td>134.045.921<\/td>\n<td>101.286.942<\/td>\n<\/tr>\n<tr>\n<td>Uzun Vadeli Y\u00fck\u00fcml\u00fcl\u00fckler<\/td>\n<td>44.759.323<\/td>\n<td>35.192.148<\/td>\n<\/tr>\n<tr>\n<td><b>\u00d6zkaynaklar<\/b><\/td>\n<td><b>366.692.089<\/b><\/td>\n<td><b>343.845.239<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>Toplam Kaynaklar<\/b><\/td>\n<td><b>545.497.333<\/b><\/td>\n<td><b>480.324.329<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>5.2. K\u00e2r veya Zarar Tablosu (Konsolide)<\/h3>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>(TL)<\/td>\n<td>01.01 &#8211; 30.09.2025<\/td>\n<td>01.01 &#8211; 30.09.2024<\/td>\n<\/tr>\n<tr>\n<td><b>Has\u0131lat<\/b><\/td>\n<td><b>523.362.988<\/b><\/td>\n<td><b>370.470.871<\/b><\/td>\n<\/tr>\n<tr>\n<td>Br\u00fct K\u00e2r<\/td>\n<td>194.535.993<\/td>\n<td>143.307.988<\/td>\n<\/tr>\n<tr>\n<td>Esas Faaliyet K\u00e2r\u0131<\/td>\n<td>61.534.494<\/td>\n<td>13.793.599<\/td>\n<\/tr>\n<tr>\n<td>Vergi \u00d6ncesi K\u00e2r \/ (Zarar)<\/td>\n<td>13.932.083<\/td>\n<td>(64.911.976)<\/td>\n<\/tr>\n<tr>\n<td><b>Net D\u00f6nem K\u00e2r\u0131 \/ (Zarar\u0131)<\/b><\/td>\n<td><b>25.517.814<\/b><\/td>\n<td><b>(66.106.501)<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>5.3. Finansal Rasyolar<\/h3>\n<table border=\"1\">\n<tbody>\n<tr>\n<td>Rasyo<\/td>\n<td>30 Eyl\u00fcl 2025<\/td>\n<td>31 Aral\u0131k 2024<\/td>\n<\/tr>\n<tr>\n<td>Cari Oran<\/td>\n<td>2,50<\/td>\n<td>2,70<\/td>\n<\/tr>\n<tr>\n<td>Asit Test Oran\u0131<\/td>\n<td>1,86<\/td>\n<td>1,67<\/td>\n<\/tr>\n<tr>\n<td>Toplam Bor\u00e7lar \/ Toplam Varl\u0131klar<\/td>\n<td>0,33<\/td>\n<td>0,28<\/td>\n<\/tr>\n<tr>\n<td>Net Bor\u00e7 \/ Kullan\u0131lan Sermaye Oran\u0131<\/td>\n<td>%10<\/td>\n<td>%0,41<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<h2>6. \u00d6nemli Geli\u015fmeler ve KAP A\u00e7\u0131klamalar\u0131 (01.01.2025 Sonras\u0131)<\/h2>\n<h3>6.1. Kazan\u0131lan \u0130haleler ve S\u00f6zle\u015fmeler<\/h3>\n<ul>\n<li><b>\u0130stanbul \u0130l Sa\u011fl\u0131k M\u00fcd\u00fcrl\u00fc\u011f\u00fc:<\/b> Ba\u011fl\u0131 ortakl\u0131k Santek Sa\u011fl\u0131k \u00fczerinden, toplam bedeli yakla\u015f\u0131k 291 milyon TL olan &#8220;Avrupa Yakas\u0131&#8221; ve &#8220;Anadolu Yakas\u0131&#8221; kemoterapi hizmet al\u0131m\u0131 s\u00f6zle\u015fmeleri imzaland\u0131.<\/li>\n<li><b>Samsun \u015eehir Hastanesi:<\/b> 115,5 milyon TL bedelli &#8220;36 Ayl\u0131k Kemoterapi \u0130la\u00e7 Haz\u0131rlama Hizmet Al\u0131m\u0131&#8221; s\u00f6zle\u015fmesi imzaland\u0131.<\/li>\n<li><b>Ondokuz May\u0131s \u00dcniversitesi:<\/b> 78,9 milyon TL bedelli &#8220;36 Ayl\u0131k Kemoterapi \u0130la\u00e7 Haz\u0131rlama ve Uygulama Hizmet Al\u0131m\u0131&#8221; s\u00f6zle\u015fmesi imzaland\u0131.<\/li>\n<li><b>DMO (Devlet Malzeme Ofisi):<\/b>\n<ul>\n<li>IVein \u00fcr\u00fcnleri i\u00e7in &#8220;Sa\u011fl\u0131k Market T\u0131bbi Malzeme \u00c7er\u00e7eve Anla\u015fmas\u0131&#8221; imzaland\u0131.<\/li>\n<li>305 hastanenin ihtiyac\u0131 i\u00e7in 38,5 milyon TL bedelli i\u011fnesiz ven valfi ihalesi kazan\u0131ld\u0131.<\/li>\n<li>219 hastanenin ihtiyac\u0131 i\u00e7in 17,2 milyon TL bedelli ek bir i\u011fnesiz ven valfi ihalesi daha kazan\u0131ld\u0131.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3>6.2. Uluslararas\u0131 Geni\u015fleme: NHS \u0130halesi<\/h3>\n<ul>\n<li><b>Tarih:<\/b> 10.10.2025<\/li>\n<li><b>Geli\u015fme:<\/b> \u015eirket, IVein markas\u0131yla kat\u0131ld\u0131\u011f\u0131 \u0130ngiltere Ulusal Sa\u011fl\u0131k Hizmetleri (NHS) taraf\u0131ndan a\u00e7\u0131lan &#8220;Needle-Free Connection Systems and Associated Products 2025&#8221; ba\u015fl\u0131kl\u0131 ihalede, teklif verdi\u011fi 97 kalemin tamam\u0131nda ba\u015far\u0131l\u0131 tedarik\u00e7i olarak se\u00e7ildi.<\/li>\n<li><b>S\u00f6zle\u015fme Detaylar\u0131:<\/b>\n<ul>\n<li><b>Toplam B\u00fct\u00e7e:<\/b> 115 Milyon GBP (yakla\u015f\u0131k 6,4 Milyar TL)<\/li>\n<li><b>S\u00fcre:<\/b> 2+2 y\u0131l (son iki y\u0131l opsiyonlu)<\/li>\n<li><b>Kapsam:<\/b> NHS a\u011f\u0131na ba\u011fl\u0131 704 hastanenin ihtiyac\u0131 kar\u015f\u0131lanacak.<\/li>\n<li><b>Beklenti:<\/b> \u0130lk y\u0131l i\u00e7in yakla\u015f\u0131k 25 Milyon GBP (yakla\u015f\u0131k 1,4 Milyar TL) tutar\u0131nda al\u0131m planlanmaktad\u0131r.<\/li>\n<\/ul>\n<\/li>\n<li><b>Stratejik Etki:<\/b> Bu geli\u015fme, \u015firketin uluslararas\u0131 pazarlardaki b\u00fcy\u00fcme stratejisi ve k\u00fcresel rekabet g\u00fcc\u00fc a\u00e7\u0131s\u0131ndan bir d\u00f6n\u00fcm noktas\u0131d\u0131r.<\/li>\n<\/ul>\n<h3>6.3. Kurumsal ve Finansal Geli\u015fmeler<\/h3>\n<ul>\n<li><b>Oncosem UK Limited Sermaye Art\u0131r\u0131mlar\u0131:<\/b> \u0130ngiltere&#8217;deki ba\u011fl\u0131 ortakl\u0131\u011f\u0131n sermayesi, d\u00f6nem i\u00e7inde ve sonras\u0131nda yap\u0131lan art\u0131r\u0131mlarla 100 GBP&#8217;den 415.100 GBP&#8217;ye \u00e7\u0131kar\u0131ld\u0131.<\/li>\n<li><b>Pay Sat\u0131\u015f Ba\u015fvurusu:<\/b> Hakim ortak Erol \u00c7EL\u0130K, B grubu paylar\u0131ndan 1.431.000 TL nominal de\u011ferli k\u0131sm\u0131n\u0131n borsada i\u015flem g\u00f6ren niteli\u011fe d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesi i\u00e7in SPK&#8217;ya ba\u015fvurdu ve ba\u015fvuru onayland\u0131.<\/li>\n<li><b>K\u00e2r Da\u011f\u0131t\u0131m Politikas\u0131:<\/b> 2024 y\u0131l\u0131 hesap d\u00f6neminde olu\u015fan zarar nedeniyle k\u00e2r pay\u0131 da\u011f\u0131t\u0131m\u0131 yap\u0131lmamas\u0131na karar verildi ve bu karar Genel Kurul&#8217;da onayland\u0131.<\/li>\n<\/ul>\n<button class=\"simplefavorite-button\" data-postid=\"417\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Favorile <i class=<\/button>","protected":false},"excerpt":{"rendered":"<p>Bir T\u00fcrk Sa\u011fl\u0131k Teknoloji Devinin Perde Arkas\u0131: Oncosem Hakk\u0131nda Muhtemelen Bilmedi\u011finiz 5 \u015eey Kemoterapi, kanser tedavisinin en kritik ve hassas a\u015famalar\u0131ndan biridir. Hastan\u0131n ya\u015f\u0131na, kilosuna ve hastal\u0131\u011f\u0131n evresine g\u00f6re milimetrik hesaplarla haz\u0131rlanan ila\u00e7 dozlar\u0131, tedavinin ba\u015far\u0131s\u0131 i\u00e7in hayati \u00f6nem ta\u015f\u0131r&#8230;. <\/p>\n","protected":false},"author":1,"featured_media":418,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[85],"class_list":["post-417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilancoanalizi","tag-oncsm"],"_links":{"self":[{"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/posts\/417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/comments?post=417"}],"version-history":[{"count":1,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/posts\/417\/revisions"}],"predecessor-version":[{"id":419,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/posts\/417\/revisions\/419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/media\/418"}],"wp:attachment":[{"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/media?parent=417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/categories?post=417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tabildot.com.tr\/marketrisk\/wp-json\/wp\/v2\/tags?post=417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}